AES-135

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AES-135 (AES135) is a novel HDAC inhibitor that biochemically inhibits HDACs 3, 6, 8 and 11 with IC50 values of 190-1100 nM.

AES-135 (AES135) is a novel HDAC inhibitor that biochemically inhibits HDACs 3, 6, 8 and 11 with IC50 values of 190-1100 nM; exhibits selective in vitro cytotoxicity in low passage patient-derived pancreatic cancer cells even in the presence of cancer-associated fibroblast (CAF) cells; exhibits favourable in vivo properties such as metabolic stability in mouse hepatocytes and bioavailability in μM concentrations in NSG mice for >10 h (IP injection); shows cytotoxicity in multiple low-passage patient-derived pancreatic cancer cell lines with IC50 of 1-4 uM in monolayer proliferation-based assays, prolongs survival significantly in orthotopic murine model of pancreatic cancer.

AES135;AES 135

Cell Cycle/DNA Damage

HDAC

HDAC

——

——

--

693.66

C33H29F6N3O5S

>98% (HPLC)

——

CC(C)(C)C1=CC=C(CN(C(CN(S(C2=CC=C(F)C=C2)(=O)=O)CC3=C(F)C(F)=C(F)C(F)=C3F)=O)C4=CC=C(C(NO)=O)C=C4)C=C1

4-(N-(4-(tert-butyl)benzyl)-2-((4-fluoro-N-((perfluorophenyl)methyl)phenyl)sulfonamido)acetamido)-N-hydroxybenzamide

(-20℃)

With Ice Pack

≥ 2 years